Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by MACFARLANE, J. D.
Right arrow Articles by BURRY, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MACFARLANE, J. D.
Right arrow Articles by BURRY, H. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1976 British Society for Rheumatology

other

GASTROINTESTINAL BLOOD LOSS ON PHENYLBUTAZONE AND FEPRAZONE

J. D. MACFARLANE, M. N. MAISEY, R. GRAHAME and H. C. BURRY

Guy's Arthritis Research Unit, Guy's Hospital Medical School London SE1 9RT

Correspondence to: Requests for reprints to J. D. Macfarlane, Department of Rheumatology, Guy's Hospital, London.

Feprazone, a new anti-inflammatory drug, is a useful antirheumatic preparation which causes little gastrointestinal upset. This short cross-over study shows no significant gastrointestinal blood loss with either feprazone or phenylbutazone by the red-cell chromium-51 labelling method.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.